Funding Details
- Awarder
- Inbox
- Date Award
- May 16, 2025
- Vertical
- Biotech
- Funding URL
- View Funding Page
Company Info
- Traction
- HAYA Therapeutics has raised USD 65 million in Series A Funding to accelerate the clinical development of its RNA-guided therapeutics platform, supporting its lead candidate HTX-001 aimed at treating heart failure.
- Organizations Involved
- Eli Lilly and Company
- Company Description
- HAYA Therapeutics is dedicated to treating heart failure through the discovery and development of innovative first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs.
- Market
- Chronic and age-related diseases
- Location
-
Switzerland
- Coinvestors
- Sofinnova Partners, Earlybird Venture Capital, Eli Lilly and Company, ATHOS, +ND Capital, Alexandria Venture Investments, LifeLink Ventures, Apollo Health Ventures, Longview Ventures, 4see ventures, BERNINA Bioinvest, Schroders Capital
Links